Skip to Content
Merck
  • Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.

Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.

ACS infectious diseases (2020-12-16)
Shipra Grover, Curtis A Engelhart, Esther Pérez-Herrán, Wei Li, Katherine A Abrahams, Kadamba Papavinasasundaram, James M Bean, Christopher M Sassetti, Alfonso Mendoza-Losana, Gurdyal S Besra, Mary Jackson, Dirk Schnappinger
ABSTRACT

MmpL3, an essential mycolate transporter in the inner membrane of Mycobacterium tuberculosis (Mtb), has been identified as a target of multiple, chemically diverse antitubercular drugs. However, several of these molecules seem to have secondary targets and inhibit bacterial growth by more than one mechanism. Here, we describe a cell-based assay that utilizes two-way regulation of MmpL3 expression to readily identify MmpL3-specific inhibitors. We successfully used this assay to identify a novel guanidine-based MmpL3 inhibitor from a library of 220 compounds that inhibit growth of Mtb by largely unknown mechanisms. We furthermore identified inhibitors of cytochrome bc1-aa3 oxidase as one class of off-target hits in whole-cell screens for MmpL3 inhibitors and report a novel sulfanylacetamide as a potential QcrB inhibitor.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1-Hydroxypiperidine, ≥96.0% (GC)